title: Perioperative therapy for muscle invasive bladder cancer.
abstract: Muscle invasive bladder cancer (MIBC) is an aggressive disease associated with poor survival rates. High rates of relapse, despite radical cystectomy, suggest that administration of systemic therapy in the perioperative period may improve clinical outcomes. Neoadjuvant treatment with cisplatin-based combination regimens is an established standard of care and has improved long-term survival in MIBC. As the use of neoadjuvant chemotherapy steadily increases, clinicians still need to decide about administering adjuvant chemotherapy to patients with high-risk disease. This review examines in detail the latest evidence available for both neoadjuvant and adjuvant chemotherapy, and highlights pertinent studies.
authors.affiliation: Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Urology, Tan Tock Seng Hospital, Singapore. Electronic address: jeffrey.leow@mail.harvard.edu.
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Leow
authors.affiliation: Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: André P
authors.initials: AP
authors.lastname: Fay
authors.affiliation: Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Mullane
authors.affiliation: Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; University Hospital del Mar-IMIM, Barcelona, Spain.
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D019990:Perioperative Care / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*
keywords: Adjuvant therapy; Chemotherapy; Neoadjuvant therapy; Radical cystectomy; Radiotherapy; Urinary bladder neoplasms